Treating
AML with
VENCLEXTA
and low-dose
cytarabine

Actor portrayal.

Remission may be possible
with VENCLEXTA + low-dose cytarabine (LDAC)

VENCLEXTA + LDAC was studied in 211 adults with newly diagnosed AML who were age 75 years or older, or who had other medical conditions that prevented the use of standard chemotherapy. In the study, 143 patients received VENCLEXTA + LDAC and 68 patients received LDAC + placebo (an inactive medication), also considered as LDAC alone.

Percentage of patients who achieved complete remission (CR) and the median length of time spent in CR:

  • For patients treated with VENCLEXTA + LDAC, 27% of 143 patients achieved CR and the median length of time spent in CR was 11 months
  • For patients treated with LDAC alone, 7% of 68 patients achieved CR and the median length of time spent in CR was 8 months
  • For patients treated with VENCLEXTA + LDAC, half of them who achieved complete remission (CR) or complete remission with partial hematologic recovery (CRh) did so in 1 month. Remissions were achieved as early as 0.7 month and as late as 5.8 months
  • VENCLEXTA + LDAC did not significantly reduce the risk of death compared to patients receiving LDAC alone

VENCLEXTA can cause serious side effects, including tumor lysis syndrome, low white blood cell count, and infections. These are not all of the possible side effects of VENCLEXTA. Talk to your healthcare provider for more information about the risks and side effects of VENCLEXTA. Please see additional important safety information below.

Median means the middle number in a group of numbers that are arranged from lowest to highest. For example, in the group of numbers 1 to 13, 7 is the median.

Remission means a decrease in or disappearance of signs and symptoms of cancer.

CR, or complete remission, means the blood count is normal, fewer than 5% of bone marrow cells are leukemia cells, and there are no signs or symptoms of leukemia elsewhere in the body. When there is CR:

  • Patients do not need to receive red blood cell transfusions
  • Patients may not need to receive platelet transfusions based on their platelet levels and no signs of bleeding

CRh, or complete remission with partial hematologic recovery, means that some remission has occurred. When there is CRh, no signs of cancer are seen, but some blood counts have not returned to normal levels.

Side effects may occur with VENCLEXTA + low-dose cytarabine.

Actor portrayal.

Learn more about treating AML with VENCLEXTA